CN101204429B - Extractive of total peony ladves flavone-glycoides, preparation method and uses thereof - Google Patents
Extractive of total peony ladves flavone-glycoides, preparation method and uses thereof Download PDFInfo
- Publication number
- CN101204429B CN101204429B CN2006101676619A CN200610167661A CN101204429B CN 101204429 B CN101204429 B CN 101204429B CN 2006101676619 A CN2006101676619 A CN 2006101676619A CN 200610167661 A CN200610167661 A CN 200610167661A CN 101204429 B CN101204429 B CN 101204429B
- Authority
- CN
- China
- Prior art keywords
- total flavone
- application
- peony leaves
- leaves total
- flavone extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000736199 Paeonia Species 0.000 title claims abstract description 58
- 235000006484 Paeonia officinalis Nutrition 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 59
- 239000011347 resin Substances 0.000 claims abstract description 33
- 229920005989 resin Polymers 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000012535 impurity Substances 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 88
- 229930003944 flavone Natural products 0.000 claims description 59
- 235000011949 flavones Nutrition 0.000 claims description 59
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 58
- 150000002212 flavone derivatives Chemical class 0.000 claims description 58
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 58
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 25
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 12
- 239000003480 eluent Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 4
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 4
- 235000008714 apigenin Nutrition 0.000 claims description 4
- 229940117893 apigenin Drugs 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000005325 percolation Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- YPWHZCPMOQGCDQ-UHFFFAOYSA-N Populnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims description 2
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000009498 luteolin Nutrition 0.000 claims description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 3
- IVCZEZUJCMWBBR-UHFFFAOYSA-N 7-O-beta-D-glucopyranosyl-7,3',4'-trihydroxyflavone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 IVCZEZUJCMWBBR-UHFFFAOYSA-N 0.000 claims 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 claims 1
- QZOVLVSTWSTHQN-UHFFFAOYSA-N luteolin 7-O-glucoside Natural products OCC1OC(Oc2cc(O)c3C(=O)C=C(C(=O)c3c2)c4ccc(O)c(O)c4)C(O)C(O)C1O QZOVLVSTWSTHQN-UHFFFAOYSA-N 0.000 claims 1
- KBGKQZVCLWKUDQ-UHFFFAOYSA-N luteolin-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C=C(C=1C=C(O)C(O)=CC=1)O2 KBGKQZVCLWKUDQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 15
- 238000005516 engineering process Methods 0.000 abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 229930003935 flavonoid Natural products 0.000 abstract 4
- 150000002215 flavonoids Chemical class 0.000 abstract 4
- 235000017173 flavonoids Nutrition 0.000 abstract 4
- 235000019441 ethanol Nutrition 0.000 description 30
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000012567 medical material Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 240000006409 Acacia auriculiformis Species 0.000 description 5
- 230000001741 anti-phlogistic effect Effects 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- -1 r Species 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 229940097766 aspirin 200 mg Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a method for separating extract of total flavonoids in purified peony leaves from new medical localities of the peony leaves and a preparation method thereof, in particular relates to the total flavonoids contentin content of the peony leaf total flavonoids contentin extract is 50 percent to 95 percent.The preparation method provided by the invention adopts resin technology in modern technology of Chinese traditional medicine so as to realize simple process, removal of a plurality of impurity and high content of active components. The invention at the same time discloses the application of the extract of the total flavonoids in the peony leaves in preparation of anti-inflammatory medicine.
Description
Technical field
The invention belongs to new Chinese medicine research and development field.Relate to a kind of medicinal part new from the Paeonia suffruticosa medical material--separate the effective site that obtains in the leaf, and its preparation method and medical usage are provided.
Background technology
Paeonia suffruticosa is not only ornamental plant, and it can also be as medicinal.The Cortex Moutan that the Pharmacopoeia of the People's Republic of China of version in 2005 records (also claiming Cortex Moutan) uses as legal Chinese crude drug, be the dry root bark of ranunculaceae peony Paeonia suffruticosa Andr., have effects such as analgesic, analgesia, antibacterial, blood pressure lowering.Cortex Moutan is as the medicinal part of Paeonia suffruticosa, the cycle of gathering is grown (3 years), get its root simultaneously, plant can't survive, therefore from rationally utilizing the angle of Chinese material medicine resource, other position that can consider to develop this medical material is as new medicinal part use, and for example the someone studies 50% decoct of leaf of paeonia suffruticosa ardr., can be used for treating dysentery; The flower of Paeonia suffruticosa can extract aromatic oil, also edible etc.But these researchs are not deep enough, to the research of the chemical constituent at these positions and pharmacologically active thereof also seldom.Therefore be necessary it is furtherd investigate, clear and definite its chemical constituent is extracted its effective site, finds new medical usage, rational exploitation and utilization Paeonia suffruticosa resource.
Summary of the invention
One of the technical problem to be solved in the present invention provides a kind of peony leaves total flavone extract, and active component wherein is to come from the leaf of Paeonia suffruticosa to put forward the effective site that thing obtains--the peony leaves total flavone.
Another technical problem that the present invention will solve provides the preparation method that is used for antiphlogistic peony leaves total flavone extract.
Having the present invention further provides with above-mentioned peony leaves total flavone is that main active is used for antiphlogistic pure Chinese medicine pharmaceutical preparation and related dose forms.
For solving the problems of the technologies described above, the present invention has studied and defined following technical scheme.
The used leaf of paeonia suffruticosa ardr. of the present invention is the dried leaves of ranunculaceae peony Paeonia suffruticosa Andr..The inventor is through years of researches, with leaf of paeonia suffruticosa ardr. is raw material, through solvent extraction, macroporous resin adsorption, solvent elution, eluent concentrate drying, obtain leaf of paeonia suffruticosa ardr. extract, contain the peony leaves total flavones content in the extract and count more than 50%～95% with apigenin.The result of study of peony leaves total flavone extract plant chemical ingredient shows, wherein mainly contains apigenin, luteolin, apigenin-7-O-glucoside, luteolin-chemical compounds such as 7-O-glucoside.
The embodiment of comparative optimization of the present invention, the peony leaves total flavone prepares by following method:
(1) extract: with the leaf of paeonia suffruticosa ardr. is raw material, water or aqueous ethanol extraction;
(2) concentrate: concentrated extracting solution, to relative density be 1.20 extractum, add water and make the extractum dissolving, centrifugal, supernatant;
(3) remove impurity: supernatant is by macroporous adsorptive resins, water, the remove impurity of aquiferous ethanol eluting successively;
(4) resolve: again with ethanol or aquiferous ethanol eluting, collect eluent, the eluent concentrate drying gets the peony leaves total flavone extract.
The concentration of alcohol of selecting for use in the leaching process in the preparation method of the present invention is X, and 0＜X≤95% is preferably 50%≤X≤95%; Extracting method can be that percolation extracts or reflux, extract,, should keep bigger ratio between ethanol and the raw material, extracts fully guaranteeing, can use the solvent extraction 2～3 times of 8～16 times of medical material weight.
Described adsorbent resin can be the resin of framework material in styrene, divinylbenzene, acrylate or the methacrylate any one or a few, specifically can comprise ZTC-1, D101, AB-8 or DM301 type resin.Be preferably the ZTC-1 resin.
Earlier with 4～10 times of water to resin volume (V/W), the aquiferous ethanol of 2～5 times of resin volumes of reuse (V/W), concentration of alcohol are X in the described remove impurity process, 10%≤X≤30%, and the impurity that is not adsorbed in the flush away post uses this method can effectively remove impurity.
Used concentration of ethanol is X in the described resolving, 40%≤X≤95%; Be preferably 40%≤X≤70%.And determine that with 4～12 times of aquiferous ethanol eluting the eluent concentrate drying gets the peony leaves total flavone extract to resin volume (V/W).
In remove impurity and desorption process, can monitor remove impurity or resolve consumption of ethanol, the time of control remove impurity or parsing by detecting in the eluent leaf of paeonia suffruticosa ardr. content of total flavone at any time.The content assaying method of peony leaves total flavone can be measured by method well known in the art, and the present invention provides a cover feasible high-performance liquid chromatogram determination method at this.Specific as follows:
1. the preparation of reference substance solution
Take by weighing the about 3mg of apigenin reference substance, the accurate title, decide, and places the 25mL measuring bottle, adds an amount of dissolve with methanol and be diluted to scale, shakes up, promptly.
2. the preparation of need testing solution
Get the about 1g of each section eluate in the peony leaves total flavone preparation process, the accurate title, decide, place the 100mL round-bottomed flask, add 80 ethanol 60mL, about 1 hour of reflux filters, twice of residue repetitive operation, merging filtrate, evaporate to dryness, residue water quantitatively are transferred in the 25mL measuring bottle, thin up is to scale again, after ultrasonic and jolting makes evenly, accurate immediately pretreated D-101 macroporous adsorptive resins on the 3mL (0.8 * 30cm, the dress 20cm of drawing, be washed to nothing alcohol with 150mL), after crossing post and adsorbing 5 times repeatedly, with 50mL 10% ethanol elution, reuse 80% ethanol 50mL eluting, collect 80% ethanol elution, evaporate to dryness, residue quantitatively is transferred in the 10mL measuring bottle with methanol, promptly gets need testing solution.
3. algoscopy
Get each about 4mL of need testing solution and reference substance solution respectively, measure absorbance respectively at 350nm wavelength place, the contrast of retinue blank solution is calculated general flavone content according to one point external standard method.
Advantage of the present invention: the present invention has developed the new medicinal part of Paeonia suffruticosa, i.e. leaf of paeonia suffruticosa ardr., and be raw material with it, extraction separation has obtained the peony leaves total flavone extract first.Because adopted the resin technology in the modernization of Chinese medicine technology, technology is simple, has removed a large amount of impurity, the content of active component is higher.
On this basis, the present invention has has also researched and proposed a kind of antiphlogistic pure Chinese medicine pharmaceutical preparation, and this Chinese medicine medicine is the effective active composition with above-mentioned peony leaves total flavone extract, and has comprised acceptable auxiliary component on the pharmaceutics.
According to technical scheme of the present invention, this Chinese medicine preparation dosage form can be oral formulations or injection preparation, and wherein oral formulations comprises capsule, soft capsule, granule, oral liquid, tablet, drop pill etc.Injection type is injection or injectable powder.Used adjuvant comprises: conventional adjuvants such as starch, sucrose, lactose, Icing Sugar, glucose, mannitol, xylitol, Polyethylene Glycol, isopropyl alcohol, soil temperature-80, glycerol, propylene glycol, microcrystalline Cellulose sodium, dextrin, cyclodextrin, sodium chloride, vitamin C, cysteine, citric acid, sodium thiosulfate, sodium sulfite, stearate and gelatin, preparation later stage preparation technology and equipment all belong to the routine techniques of pharmaceutical field, the present invention does not limit this, so will not describe in detail at this.
Peony leaves total flavone extract of the present invention and pharmaceutical preparation thereof have antiphlogistic effects preferably.The therapeutic effect that contains the pharmaceutical composition of peony leaves total flavone extract for the ease of understanding, the inventor mainly adopts the mice ear inflammatory model due to the dimethylbenzene to carry out the antiinflammatory pharmacodynamics test, adopted peony leaves total flavone extract (by the preparation of the embodiment 1 method) gastric infusion of various dose in the test, is observation index with same position with the mice auricle weight under the homalographic, research peony leaves total flavone extract xylol causes the influence of mice ear degree, specifically tests as follows:
Test example 1 peony leaves total flavone extract xylol causes the influence of mice ear
Choose 60 ICR mices, be divided at random model group, positive drug (aspirin 200mg/kg) group, peony leaves total flavone extract little (10mg/kg), in (50mg/kg), big (100mg/kg) dosage group, 12 every group.Each treated animal all takes to irritate the stomach administration, administration volume 0.2mL/10g, and matched group gives isopyknic distilled water, and 1 time/day, continuous 7 days.1h only gives the mouse peritoneal injecting anesthetic with the pentobarbital sodium of 5mg/mL with 0.35ml/ behind the 7th day medicine.Dimethylbenzene with 100% is applied to mouse right ear 0.02mL/ and only causes inflammation (positive and negative is respectively 0.01mL), and left ear is left intact.Cause and put to death mice behind the scorching 45min and with the 8mm card punch mice left and right sides ear is taken off same area and auricle of the same area and weigh, deduct left auricle weight with auris dextra sheet weight and be swelling degree (mg).Each is organized data and represents with mean ± standard deviation, carries out statistical analysis according to the method for t check between group and handles.Experimental result is as shown in the table:
Table 1 peony leaves total flavone extract xylol causes the influence (x ± s) of mice ear
Annotate: compare with model group
*P＜0.05
*P＜0.01
* *P＜0.001; Auris dextra sheet weight and left auricle weight ratio are
▲ ▲P＜0.01
By table 1 as seen, each is organized mice and gives behind the dimethylbenzene auris dextra sheet and left auricle relatively, and weight obviously increases, and learns by statistics and handles the difference that significance is all arranged, and prove that model successfully.Aspirin group and model group compare, and auris dextra sheet weight and swelling degree obviously reduce, and learn processing difference by statistics and have significance (P＜0.05); Each dosage group of peony leaves total flavone extract and model group relatively, auris dextra sheet weight and ear swelling degree all have and alleviate, and learn by statistics to handle difference and all have significance (P＜0.05 or P＜0.001).
Dimethylbenzene has stronger proinflammatory effect, the auricle that spreads upon mice can cause the ear skin telangiectasis, and vascular permeability increases, and causes ear swelling then, the influence of the degree by observing medicine xylol induced mice ear swelling can reflect the antiphlogistic effects of medicine.This result of study prompting, the peony leaves total flavone has antiinflammatory pharmacological action preferably.
The specific embodiment
Describe the enforcement of technical solution of the present invention by the following examples in detail, but should not limit practical range of the present invention with this.
Embodiment 1: the preferred for preparation method of peony leaves total flavone extract
Get the leaf of paeonia suffruticosa ardr. medicinal powder, extract 3 times each 1 hour with 14 times of medical material amount 50% alcohol heating reflux.Filter, with 60 ℃ of decompression recycling ethanols of ethanol extract, extracting solution is concentrated into the extractum of relative density 1.20 (25 ℃ of mensuration), add 5 times of water (60 ℃) and make the extractum dissolving to medical material weight, centrifugal, supernatant is by the ZTC-1 resin column, with 4 times to the water of resin volume (V/W) and 30% ethanol of 5 times of resin volumes (V/W), the impurity that is not adsorbed in the flush away post is resolved with 6 times of 40% ethanol to resin volume (V/W) then.Collect eluent, concentrating under reduced pressure, vacuum drying gets the peony leaves total flavone extract, and wherein the leaf of paeonia suffruticosa ardr. content of total flavone is 55%.
Embodiment 2: the preferred for preparation method of peony leaves total flavone extract
Get the leaf of paeonia suffruticosa ardr. medicinal powder, extract 2 times each 1 hour with 8 times of medical material amount 95% alcohol heating reflux.Filter, with 60 ℃ of decompression recycling ethanols of ethanol extract, extracting solution is concentrated into the extractum of relative density 1.20 (25 ℃ of mensuration), add 10 times of water (60 ℃) and make the extractum dissolving to medical material weight, centrifugal, supernatant is by the D101 resin column, with 6 times to the water of resin volume (V/W) and 10% ethanol of 2.5 times of resin volumes (V/W), the impurity that is not adsorbed in the flush away post is resolved with 10 times of 70% ethanol to resin volume (V/W) then.Collect eluent, concentrating under reduced pressure, vacuum drying gets the peony leaves total flavone extract, and wherein the leaf of paeonia suffruticosa ardr. content of total flavone is 60%.
Embodiment 3: the preferred for preparation method of peony leaves total flavone extract
Get the leaf of paeonia suffruticosa ardr. medicinal powder, with 10 times of medical material amount 70% ethanol, percolation extracts.With 60 ℃ of decompression recycling ethanols of ethanol extract, extracting solution is concentrated into the extractum of relative density 1.20 (25 ℃ of mensuration), add 8 times of water (60 ℃) and make the extractum dissolving to medical material weight, centrifugal, supernatant is by the DM301 resin column, with 10 times to the water of resin volume (V/W) and 20% ethanol of 2 times of resin volumes (V/W), the impurity that is not adsorbed in the flush away post, resolve with 4 times of 60% ethanol then to resin volume (V/W), collect eluent, concentrating under reduced pressure, vacuum drying, get the peony leaves total flavone extract, wherein the leaf of paeonia suffruticosa ardr. content of total flavone is 90%.
Embodiment 4: the preferred for preparation method of peony leaves total flavone extract
Get the leaf of paeonia suffruticosa ardr. medicinal powder, with 16 times of medical material calorimetric water, percolation extracts.Extracting solution is concentrated into 10 times of medical material amounts, centrifugal, supernatant is by the AB-8 resin column, with 8 times to the water of resin volume (V/W) and 30% ethanol of 2.5 times of resin volumes (V/W), the impurity that is not adsorbed in the flush away post is resolved with 8 times of 95% ethanol to resin volume (V/W) then.Collect eluent, concentrating under reduced pressure, vacuum drying gets the peony leaves total flavone extract, and wherein the leaf of paeonia suffruticosa ardr. content of total flavone is 75%.
Embodiment 5: the preferred dosage form capsule of peony leaves total flavone
Get the peony leaves total flavone extract 100g of embodiment 1 method preparation, 60 ℃ of dryings grind, and cross 80 mesh sieves, the medical starch 98g and the magnesium stearate 2g that added 80 mesh sieves, mix homogeneously is made soft material in right amount with 85% ethanol, crosses 30 mesh sieve system granules, oven dry, make moisture less than 5%, cross 40 mesh sieve granulate, be sub-packed in No. 3 capsules.Every capsules contains peony leaves total flavone extract 0.1g, uses aluminium plastic composite packaging, promptly.
Embodiment 6: the preferred dosage form tablet of peony leaves total flavone
Get the peony leaves total flavone extract 30g of embodiment 1 method preparation, add starch 30g, microcrystalline Cellulose 10g granulates with 12 mesh sieves in right amount with 10% starch slurry, and dry below 55 ℃, dry granular adds magnesium stearate, granulate, and mixing, tabletting, promptly.
Embodiment 7: the preferred dosage form injection of peony leaves total flavone
Get the peony leaves total flavone extract 100g of embodiment 3 methods preparation, add sodium chloride 8g, be dissolved in an amount of water for injection stirring and dissolving, add water for injection to 1000ml, stir, filter, filtrate is sub-packed in the cillin bottle, presses the lyophilizing of freeze-dried powder technology, makes freeze-dried powder.
Claims (16)
1. the application of peony leaves total flavone extract in the preparation anti-inflammatory drug.
2. the application of claim 1, containing peony leaves total flavone percentage by weight in the described peony leaves total flavone extract is 50%～95%.
3. the application of claim 2 mainly contains apigenin, luteolin, apigenin-7-O-glucoside and luteolin-7-O-glucoside in the described peony leaves total flavone extract.
4. the application of one of claim 1 to 3 prepares the method for described peony leaves total flavone extract, it is characterized in that:
(1) extract: with the leaf of paeonia suffruticosa ardr. is raw material, water or aqueous ethanol extraction;
(2) concentrate: concentrated extracting solution, to relative density be 1.20 extractum, add water and make the extractum dissolving, centrifugal, supernatant;
(3) remove impurity: supernatant is by macroporous adsorptive resins, water, the remove impurity of aquiferous ethanol eluting successively;
(4) resolve: again with ethanol or aquiferous ethanol eluting, collect eluent, the eluent concentrate drying gets the peony leaves total flavone extract.
5. the application of claim 4 prepares the method for described peony leaves total flavone extract, it is characterized in that being extracted as percolation and extracts or reflux, extract.
6. the application of claim 4 prepares the method for described peony leaves total flavone extract, it is characterized in that used concentration of ethanol is X in the leaching process, 0＜X≤95%.
7. the application of claim 6 prepares the method for described peony leaves total flavone extract, it is characterized in that concentration of ethanol used in the leaching process is X, 50%≤X≤95%.
8. the application of claim 4 prepares the method for described peony leaves total flavone extract, it is characterized in that described resin is that in styrene, divinylbenzene, acrylate or the methacrylate any one or a few is the resin of framework material.
9. the application of claim 8 prepares the method for described peony leaves total flavone extract, it is characterized in that the adsorbent resin that is adopted is ZTC-1, D101, AB-8 or DM301 type resin.
10. the application of claim 4 prepares the method for described peony leaves total flavone extract, it is characterized in that concentration of alcohol used in the remove impurity process is X, 10%≤X≤30%.
11. the application of claim 4 prepares the method for described peony leaves total flavone extract, it is characterized in that concentration of alcohol used in the resolving is X, 40%≤X≤95%.
12. the application of claim 11 prepares the method for described peony leaves total flavone extract, it is characterized in that concentration of ethanol used in the resolving is X, 40%≤X≤70%.
13. the application of one of claim 1 to 3, described anti-inflammatory drug is made by acceptable adjuvant on peony leaves total flavone extract and the pharmaceutics.
14. the application of claim 13, described anti-inflammatory drug are oral formulations or ejection preparation.
15. the application of claim 14 is characterized in that described oral formulations is capsule, granule, oral liquid, tablet, drop pill.
16. the application of claim 14 is characterized in that described ejection preparation is injectable powder or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101676619A CN101204429B (en) | 2006-12-21 | 2006-12-21 | Extractive of total peony ladves flavone-glycoides, preparation method and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006101676619A CN101204429B (en) | 2006-12-21 | 2006-12-21 | Extractive of total peony ladves flavone-glycoides, preparation method and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101204429A CN101204429A (en) | 2008-06-25 |
| CN101204429B true CN101204429B (en) | 2011-06-01 |
Family
ID=39565057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006101676619A Active CN101204429B (en) | 2006-12-21 | 2006-12-21 | Extractive of total peony ladves flavone-glycoides, preparation method and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101204429B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101558880B (en) * | 2009-02-23 | 2012-09-26 | 铜陵凯润牡丹生物医药科技有限公司 | Teabag containing paeoniifolia for beautifying skin and manufacturing method thereof |
| CN102335276B (en) * | 2011-10-10 | 2014-06-04 | 杨永庆 | Preparation method and application of tree peony extract and composition of tree peony extract |
| CN109293615A (en) * | 2018-12-04 | 2019-02-01 | 安徽四平食品开发有限责任公司 | A method of extraction prepares apiolin from Chinese celery |
| CN112174976A (en) * | 2020-11-19 | 2021-01-05 | 江西中医药大学 | Dibenzofuran lignan separated from water cress, and its preparation method and application in resisting gouty arthritis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243742A (en) * | 1999-02-04 | 2000-02-09 | 高福兴 | Natural peony juice and its extraction process |
-
2006
- 2006-12-21 CN CN2006101676619A patent/CN101204429B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243742A (en) * | 1999-02-04 | 2000-02-09 | 高福兴 | Natural peony juice and its extraction process |
Non-Patent Citations (4)
| Title |
|---|
| 杨树声 等.紫斑牡丹各部位中丹皮酚和芍药苷的含量分析.西北药学杂志16 3.2001,16(3),108-109. |
| 杨树声等.紫斑牡丹各部位中丹皮酚和芍药苷的含量分析.西北药学杂志16 3.2001,16(3),108-109. * |
| 蔡健 等.黄酮提取工艺研究进展.淮阴工学院学报12 5.2003,12(5),82-85. |
| 蔡健等.黄酮提取工艺研究进展.淮阴工学院学报12 5.2003,12(5),82-85. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101204429A (en) | 2008-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100475243C (en) | Hypoglycemic, antilipenic and hemopathy-treating glutinous rehmannia extract and preparing method thereof | |
| CN103006878B (en) | A kind of fresh rehmannia root total glycosides extractive and preparation method and application | |
| CN102078443B (en) | Medicine composition, application and preparation thereof | |
| CN101204429B (en) | Extractive of total peony ladves flavone-glycoides, preparation method and uses thereof | |
| CN103191289B (en) | Synchronous preparation method of four effective parts in medicine pair of common anemarrhena rhizome and amur corktree bark and application thereof | |
| CN101057890B (en) | Traditional Chinese medicinal composition for treating coronary heart disease and its preparation method, preparations and its application | |
| CN1706397B (en) | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte | |
| CN101164566B (en) | Peony leaves total glycoside extract, its preparation method and application | |
| CN101234147B (en) | Method of preparing total flavones of tropaeolum for injections | |
| CN102134268A (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| CN1314403C (en) | Composition of paeoniflorin and albiflorin and its preparation method | |
| CN107929544B (en) | Preparation method and application of mileanine part and monomer in bletilla plants | |
| CN104546995B (en) | A kind of medicinal usage of emblic extract | |
| CN102976943B (en) | The alpha-crystal form material of salvianolic acid A, method for making and pharmaceutical composition and purposes | |
| CN100371340C (en) | Production of Rhizoma Picrorhizae glucoside II monomer and its drug form for treating hepatitis B | |
| CN101618069B (en) | Capsule preparation for treating bruise as well as bleeding and easing pain and preparation method and use thereof | |
| CN100584358C (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN101269123A (en) | Secondary development novel technique for thirst eliminating capsule for lowering blood sugar | |
| CN101375954B (en) | Medicament composition, preparation method thereof and use | |
| CN101176755B (en) | Application of meletin-7-0-glycoside in mass control of cudrania tricuspidata or preparations thereof | |
| CN100421685C (en) | Chinese material medica preparation in use for treating infection of influenza virus, and preparation method | |
| CN100411653C (en) | Chinese medicine composition for treating diabetes mellitus | |
| CN101204430A (en) | Extractive of total peony ladves glucoside, preparation method and uses thereof | |
| CN102552297B (en) | Application of medicinal composition in preparation of alpha-glucuroide inhibitor medicines | |
| CN107252440A (en) | A kind of preparation method and purposes of the Hickory Leaves general flavone with hypoglycemic effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIDA SHIJIA TECHNOLOGY DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20150121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150121 Address after: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee after: Beida Shijia Technology Development Co. Ltd. Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |
|
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 102206, 20 floor, No. 6, life road, Beijing, Changping District, 3 Patentee after: Beida Shijia Technology Development Co. Ltd. Address before: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee before: Beida Shijia Technology Development Co. Ltd. |